Cigna Corp (CI)
NYSE:CI
Want to see CI full AI Analyst Report?
CI Stock Chart & Stats
$278.64
-$1.43(-0.51%)
At close: 4:00 PM EST
$278.64
-$1.43(-0.51%)
Day’s Range― - ―
52-Week Range$239.51 - $350.00
Previous CloseN/A
Volume191.22K
Average Volume (3M)1.57M
Market Cap
$74.59B
Enterprise Value$100.86B
Total Cash (Recent Filing)$7.85B
Total Debt (Recent Filing)$30.90B
Price to Earnings (P/E)10.6
Beta0.27
Next Earnings
Jul 30, 2026EPS Estimate
7.59Next Dividend Ex-DateN/A
Dividend Yield2.21%
Share Statistics
EPS (TTM)7.79
Shares Outstanding263,660,770
10 Day Avg. Volume1,261,260
30 Day Avg. Volume1,570,479
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)1.75
Price to Sales (P/S)0.27
P/FCF Ratio8.73
Enterprise Value/Market Cap1.35
Enterprise Value/Revenue0.36
Enterprise Value/Gross Profit3.90
Enterprise Value/Ebitda8.45
Forecast
1Y Price Target
$340.27Price Target Upside22.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
EPS Forecast (FY)30.35
Revenue Forecast (FY)$282.31B
Bulls Say, Bears Say
Bulls Say
ASO And Stop-loss Commercial StrategyAnalyst highlights that focusing on administrative services only and stop-loss products for small and mid-sized employers is a capital-efficient way for Cigna to gain share in faster-growing commercial segments and produce more profitable customers.
PBM Pricing Model And MarginsAnalyst expects Cigna's shift to a rebate-free, fee-based pharmacy benefit manager model to reduce regulatory risk and support margin improvement for large-scale operators, which could lift the segment's valuation.
Regulatory ClarityAnalyst notes the FTC settlement removes a major legal overhang for Cigna's pharmacy benefit manager business, allowing investor attention to shift toward growth prospects and potential valuation recovery.
Bears Say
Biosimilars CompetitionAnalyst warns that increased biosimilar competition has acted as a hidden headwind to pharmacy benefit manager profitability and could continue to pressure overall margins despite recovery in specialty services.
Commercial Market SaturationAnalyst points out that the commercial insurance market is largely saturated with limited enrollment growth, which constrains total market expansion and limits upside for a commercial-focused insurer like Cigna.
Reserve Volatility And Stop-loss UncertaintyAnalyst notes that sizable reserve changes driven by stop-loss seasonality and lagged claim payments create earnings and reserve uncertainty that investors will need to monitor.
Cigna News
CI FAQ
What was Cigna Corp’s price range in the past 12 months?
Cigna Corp lowest stock price was $239.51 and its highest was $350.00 in the past 12 months.
What is Cigna Corp’s market cap?
Cigna Corp’s market cap is $74.59B.
When is Cigna Corp’s upcoming earnings report date?
Cigna Corp’s upcoming earnings report date is Jul 30, 2026 which is in 87 days.
How were Cigna Corp’s earnings last quarter?
Cigna Corp released its earnings results on Apr 30, 2026. The company reported $7.79 earnings per share for the quarter, beating the consensus estimate of $7.598 by $0.192.
Is Cigna Corp overvalued?
According to Wall Street analysts Cigna Corp’s price is currently Undervalued.
Does Cigna Corp pay dividends?
Cigna Corp pays a Quarterly dividend of $1.51 which represents an annual dividend yield of 2.21%. See more information on Cigna Corp dividends here
What is Cigna Corp’s EPS estimate?
Cigna Corp’s EPS estimate is 7.59.
How many shares outstanding does Cigna Corp have?
Cigna Corp has 263,660,770 shares outstanding.
What happened to Cigna Corp’s price movement after its last earnings report?
Cigna Corp reported an EPS of $7.79 in its last earnings report, beating expectations of $7.598. Following the earnings report the stock price went down -0.595%.
Which hedge fund is a major shareholder of Cigna Corp?
Currently, no hedge funds are holding shares in CI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cigna Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$340.27 (22.12% Upside)
$340.27 (22.12% Upside)
Blogger Sentiment
Bullish
CI Sentiment 83%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 2.1%
Last 30 Days ▲ 2.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Company Description
Cigna Corp
The Cigna Group provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care delivery and management, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's Cigna Healthcare segment offers medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as individual health insurance plans to on and off the public exchanges; and health care coverage in its international markets, as well as health care benefits for mobile individuals and employees of multinational organizations. The company also offers permanent insurance contracts sold to corporations to provide coverage on the lives of certain employees for financing employer-paid future benefit obligations. It distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
CI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum: consolidated revenue and EPS growth, a raised full-year EPS outlook, robust specialty and Cigna Healthcare performance, and meaningful innovation (rebate-free pharmacy model and AI-enabled savings). Primary headwinds centered on near-term PBS earnings pressure (28% decline) due to renewals and transition investments, a material special-items charge ($322M after-tax), and portfolio exits/strategic reviews that reduce near-term scope. Management presented these challenges as deliberate and manageable trade-offs to sharpen focus and accelerate long-term value creation.View all CI earnings summariesCI Stock 12 Month Forecast
Average Price Target
$340.27
▲(22.12% Upside)
Technical Analysis
Ownership Overview
0.34% Insiders
28.83% Mutual Funds
3.05% Other Institutional Investors
43.66% Public Companies and Individual Investors